Liposarcomas - proliferation, senescence and the role of DDIT3 by Kåbjörn Gustafsson, Christina
 Liposarcoma 
Proliferation, senescence and the role of 
DDIT3 
 
 
 
Christina Kåbjörn Gustafsson 
 
 
 
Department of Pathology 
Institute of Biomedicine, 
Sahlgrenska Academy at University of Gothenburg 
 
 
 
 
 
 
Gothenburg 2014 
Gothenburg 2014 
Cover illustration: NCAM –positive human muscle derived cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liposarcoma 
© Christina Kåbjörn Gustafsson 2014 
christina.kabjorn@vgregion.se 
 
ISBN 978-91-628 -8831-2 
 
http://hdl.handle.net/2077/34834 
 
Printed in Gothenburg, Sweden 2014 
Kompendiet Aidla Trading AB 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my surprise! 
And to my dear, big family all over Sweden, especially my 
husband, Reine, and my children, Sofie and Ruben  
  
 
Liposarcoma 
Proliferation, senescence and the role of DDIT3 
Christina Kåbjörn Gustafsson 
ABSTRACT 
Lipomatous tumors comprise benign and malignant forms called lipomas and 
liposarcomas. Myxoid/round cell liposarcoma (MLS/RCLS) is the second most 
common liposarcoma and is characterized by the fusion oncogenes FUS-DDIT3 or 
EWSR1-DDIT3. To understand the morphology of MLS we investigated the role of 
the FUS-DDIT3 fusion in the development of MLS/RCLS in FUS-DDIT3- and 
DDIT3-transfected human HT1080 sarcoma cells. Cells expressing FUS-DDIT3 and 
DDIT3 grew as liposarcomas in immune-deficient mice. Microarray-based 
comparison of HT1080, the transfected cells, and an MLS/RCLS-derived cell line 
showed that the FUS-DDIT3- and DDIT3-transfected variants shifted toward an 
MLS/RCLS-like expression pattern. DDIT3-transfected cells responded in vitro to 
adipogenic factors by accumulation of fat and transformation to a lipoblast-like 
morphology. In conclusion, the fusion gene and normal DDIT3 induce a liposarcoma 
phenotype when expressed in a primitive sarcoma cell line. MLS/RCLS may develop 
from cell types other than preadipocytes. In addition, development of lipoblasts and 
the typical MLS/RCLS capillary network could be an effect of the DDIT3 
transcription factor partner of the fusion oncogene. Further immunohistochemical 
investigation of the expression of the DDIT3 protein showed that major cell 
subpopulations of well differentiated tumors and MLS/RCLS tumors were found to 
express DDIT3 or the derived fusion protein. Our results suggest a dual, promoting 
and limiting, role for DDIT3 in formation of lipoblasts and liposarcoma morphology. 
Most liposarcoma types are characterized by genomic instability caused by impaired 
TP53 function. Further analysis of TP53 in MLS/RCLS with mass spectrometry, 
immunoblotting and immunohistochemistry show that a normal TP53 protein is 
produced in three of four MLS cell lines. This shows that the TP53 system is 
functional in the majority of MLS cases. MLS/RCLS tumors express proteins 
involved in cell senescence. In a study of 17 MLS/RCLS cases, large subpopulations 
of tumor cells expressed the RBL2 pocket protein together with senescence-
associated heterochromatin binding protein 1γ and IL8 receptor β. The expression 
pattern suggests that MLS/RCLS tumors contain large subpopulations of senescent 
cells compatible with the slow growth of this tumor type.  
 
Keywords: Liposarcoma, FUS-DDIT3, TP53, senescence 
ISBN: 978-91-628 -8831-2 
 
SAMMANFATTNING PÅ SVENSKA 
Cancer är en elakartad tumör som kan sprida sig i kroppen och uppstår på 
grund av genetiska skador (mutationer) i en normal cells arvsmassa (DNA). 
Arvsmassan innehåller mer än 20 000 olika gener som styr alla de processer 
som pågår i en cell. Det är framför allt gener som kontrollerar cellförökning 
som är skadade i cancer och en av de viktigaste bland dessa gener är TP53. 
Den kallas för arvsmassans väktare och det är ofta just TP53 som har en 
mutation, vilket leder till en okontrollerad cellförökning och ansamling av 
andra mutationer.  Idag vet man att det inte räcker med bara en muterad gen 
utan flera mutationer i olika gener krävs för canceruppkomst. De vanligaste 
tumörformerna utgår från hud, slemhinnor och organ. Mindre vanliga 
tumörformer är tumörer som växer i kroppens ben- och mjukdelar och 
elakartade former här kallas ofta sarkom. Fettartade tumörer, liposarkom, är 
den vanligaste typen av mjukdelssarkom i människa och en av de allra 
vanligaste är myxoida liposarkom (MLS).  
I den här avhandlingen har vi undersökt olika varianter av fettumörer med 
tonvikt på MLS. Den här tumören har en specifik genetisk förändring där två 
gener smälter samman och bildar en ny gen, en fustionsgen, kallad FUS-
DDIT3. De flesta MLS bär på denna fusionsgen. Vi har kunnat visa att 
fusionsproteinet FUS-DDIT3 och normalt DDIT3 har en instruerande effekt 
för tumörernas fettlika utseende/fenotyp. Ett onormalt uttryck av DDIT3, som 
del av fusionsproteinet eller som ett resultat av genetiska omkastningar, 
bidrar till differentieringen mot fett, viket oftast karakteriserar de här 
tumörtyperna. Myxoida liposarkom är långsamväxande tumörer och vi har 
undersökt 17 tumörer av typen MLS/RCLS med avseende på proteiner 
associerade med tillväxtkontroll och irreversibel vilofas (senescence). 
Resultaten pekar på att en stor population av tumörceller är senescenta. 
Tidigare publikationer har rapporterat att mutationer av TP53 är vanliga 
medan andra publikationer har rapporterat att TP53 mutationer är sällsynta i 
MLS/RCLS. Här visar vi att funktionellt TP53-protein produceras i 3 utav 4 
MLS-cellinjer, vilket också förklarar varför majoriteten av dessa tumörer är 
strålnings-känsliga. Myxoida liposarkom växer vanligen inuti muskulatur och 
framförallt i djupa lårmuskler. För att förstå biologin bakom uppkomsten av 
en tumör är det viktigt att få kunskap om ursprungscellens egenskaper. Vad 
gäller MLS/RCLS kan man misstänka att en i muskelvävnad vanligt 
förekommande celltyp, efter genetiska förändringar, ger upphov till dessa 
tumörer. Vi har extraherat och jämfört genetiskt material från normala odlade 
muskelceller och odlade MLS-tumörceller. Vi hittade att MLS-tumörceller 
har genetiska likheter både med förstadier till muskelceller och med mer 
omogna muskelderiverade celler. 
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ABBREVIATIONS  
APC Anaphase promoting complex 
CCNA Cyclin A 
CEBP CCAAT/enhancer-binding protein 
CDC2 Cyklin dependent kinase 1 
CDK Cyclin dependent kinase 
DDIT3 DNA-damage-inducible transcript 3 
DDLS Dedifferentiated liposarcoma 
DNA Deoxyribonucleic acid 
DP1 Transcription factor dimerization partner 1 
E2F Transcription factor IIF 
EWS Ewing sarcoma breakpoint region 1 
FISH Fluorescence in situ hybridization 
FUS Fused in Sarcoma 
G1 First gap phase 
G2 Second gap phase 
HMGA2 High-mobility group AT-hook 2 
IHC Immunohistochemistry 
MAPK Mitogen-activated protein kinases 
MAX MYC associated factor X 
MDM2 Mouse double minute 2 homolog 
 
 MDSC Muscle derived stem cell 
MFH Malignant fibrous histiocytoma 
MLS Myxoida liposarcoma 
mTOR Mammalian target of rapamycin 
MYC V-Myc avian myelocytomatosis viral oncogene homolog 1 
NCAM Neural Cell Adhesion Molecule 
NFkB Nuclear factor kappa-light-chain-enhancer of activated B cells 
PLS                Pleomorfic liposarcoma 
PP Indicates Phosphorylation 
PPAR Peroxisome proliferator-activated receptor 
RB Retinoblastoma protein 
RCLS Round cell liposarcoma 
RNA Ribonucleic acid 
SASP Senescence-associated secretory phenotype  
S-phase DNA-synthesis phase 
SP Side population 
WDLS Well differentiated liposarcoma 
 
 
 
 
 
  
 1 INTRODUCTION 
The human body is built by tissue derived from the three early embryonic 
germ cell layers: the ectoderm, the endoderm, and the mesoderm [1].  The 
embryonic differentiation of tissues and organs is a vulnerable path where 
genetic conditions and genetic alterations may cause undesired effects, and 
even cancer. Malignant tumors is a heterogeneous group of diseases and 
characterized by uncontrolled growth and spread of abnormal cells. The 
development of cancer, carcinogenesis, is a multistep genetic process. It 
initiates in a single normal cell and gradually transforms its progeny into 
malignant counterparts by sequential genetic changes [2, 3]. Cancer causing 
mutations affects two main classes of genes. They activate proto-oncogenes 
and inactivate tumor suppressor genes [4-6].  
1.1 Characteristics of cancer development 
Although cancer is a group of heterogeneous diseases it has been proposed 
that several major alterations in cell physiology are required for cancer 
development [7, 8] and they are:  
• Limitless replicative potential. Normal cells carry a program 
preventing them from limitless division.  
• Resisting of cell death. A normal cell respond to signals 
from the intra-and extracellular environment and if abnormal 
signals, a programmed cell death will occur, apoptosis. 
• Self-sufficiency in growth signals. A normal cell requires 
growth-promoting signals from the environment before they 
can actively proliferate. 
• Insensitivity to growth suppressors. Tissue homeostasis is 
normally maintained by antiproliferative signals that induce 
cell-arrest or differentiation. 
• Sustained angiogenesis. Oxygen and nutrients, as well as 
waste disposal, are crucial for proper cell function and 
survival. 
• Deregulated cellular energetics. Normal cells extract their 
energy by oxidative phosphorylation.  
• Tissue invasion and metastasis. Normal cells maintain tissue 
architecture and borders. 
 
1.2 Tumor classification 
Tumors can arise and develop in any tissue or organ. The most common 
tumors, derived from the ectoderm and classified as carcinomas, account for 
more than 80% of all cancer-related deaths in the Western world [9]. These 
tumors are further separated into two main categories, where squamous cell 
carcinomas are derived from the epithelia lining body surfaces, while 
adenocarcinomas originate from glandular epithelia, mostly in organs. The 
remaining malignant tumors arise from nonepithelial tissues. A group of non-
epithelial cancers arise in the various cell types that make up blood-forming 
tissues and cells of the immune system. These are called leukemias and 
lymphomas respectively. Another group of nonepithelial tumors develops 
from cells in the central and peripheral nervous system and are termed 
neuroectodermal tumors. Tumors derived from the mesoderm, for example 
fat, muscle, cartilage, and bone,  belong in the group of mesenchymal tumors, 
and the malignant mesenchymal tumors are often called soft tissue sarcomas 
[10]. 
Soft tissue sarcoma is a heterogeneous group of malignant tumors that 
constitutes less than 1% of all malignant tumors in Sweden [11]. Among 
these, liposarcoma is the most common type of soft tissue sarcoma in humans 
and constitutes about 10% - 18% of soft tissue sarcomas [12]. The two most 
common types are well-differentiated/dedifferentiated liposarcoma 
(WDLS/DDLS) and myxoid/round cell liposarcoma (MLS/RCLS). These 
tumors develop in different locals and in different kinds of mesenchymal 
tissue. The benign and most common fatty tumor is the lipoma, usually 
growing slowly as a lump in the subcutaneous fat, mostly in the arm, leg, or 
back. 
1.3 Histological subtypes of liposarcoma 
There are several histological subtypes of liposarcomas and the current 
nomenclature is based on the World Health Organization classification, 
(WHO), Table 1.  They each have different appearance and clinical behavior 
[13].  The histopathological low-grade tumors constitute WDLS (grade I) and 
MLS with less than 5% round cells (grade II), and the high-grade group 
consists of MLS with more than 5% round cells (grade III or IV) and DDLS 
and PLS (grade IV). The higher the grade the more aggressive the behavior. 
 
 
 
 Atypical lipomatous tumors/Well-differentiated liposarcom (WDLS) 
Dedifferentiated liposarcoma (DDLS) 
Myxoid liposarcoma (MLS) 
Pleomorphic liposarcoma (PLS) 
 
Table 1. Liposarcoma subtypes, according to the WHO classification of 2013 
 
1.3.1 Well differentiated liposarcoma (WDLS) 
There are four different histological subtypes of WDLS with limited clinical 
importance, but representing 40% - 45% of all liposarcomas. The lipoma-like 
WDLS has a characteristic morphology with relatively mature fat cells 
varying in size, and where mono-or multi-vacuolated lipoblasts may be 
found. One sees atypical enlarged nuclei, few mitotic figures, and minimal 
myxoid or fibrous zones.  
Most often WDLS presents as large, deep-seated lesions of the thigh 
followed by lesions in the retroperitoneum. They may recur locally, but do 
not metastasize unless they undergo dedifferentiation, which is most common 
in the retroperitoneum [11, 12]. Atypical lipomatous tumor is a synonymous 
term preferred to be used for lesions arising at surgically amenable locations 
whereas WDLS is preferred in reference to lesions arising in the 
retroperitoneum and mediastinum, because of their association with 
recurrence and significant mortality. 
 
At chromosomal level these tumors usually show the presence of extra ring 
and/or giant marker chromosomes invariably containing amplified sequences 
originating from the 12q (14-15) region [12, 14]. The gene MDM2 (12q15) is 
consistently amplified and overexpressed and is considered the main driver 
gene of the 12q amplicon. Elevated MDM2 expression blocks TP53 function. 
Further discussions are in section 1.7.3. Other genes located in the 12q (14-
15) region, for instance, CDK4 and HMGA2, are frequently co-amplified with 
MDM2. No recurrent fusion gene is recognized. 
1.3.2 Dedifferentiated liposarcoma (DDLS) 
Morphologically, DDLS represents transition areas from WDLS to non-
lipogenic sarcoma, which in most cases resembles high-grade fibrosarcoma 
or pleomorphic undifferentiated sarcoma (previously malignant fibrous 
histiocytoma, MFH) [12]. DDLS is a high-grade tumor most commonly 
occurring in the retroperitoneum, where it is associated with a significantly 
worse survival. 
Like WDLS, these tumors also show the presence of extra ring and/or giant 
marker chromosomes derived from 12q. Amplification of MDM2 and CDK4 
is frequently seen. No specific fusion gene is recognized. 
1.3.3 Myxoid liposarcoma (MLS) 
About 40% of all liposarcomas consists of MLS. They have a unique 
morphology with hypocellular spindle cell proliferation in a myxoid 
background with a characteristic plexiform capillary bed. There are immature 
fat cells, lipoblasts around vessels or at the periphery of the tumor. The 
presence of hypercellular areas with undifferentiated round cell morphology 
is classified as mixed myxoid/round cell variant (MLS/RCLS) if the 
population of round cells ranges between 5% and 80%, and as pure RCLS if 
more than 80%. MLS is classified as a high-grade tumor, if there is a 
population of 5% round cells or more [12].   
Classical MLS has a good prognosis with low metastatic rate, whereas round 
cell type with necrosis and mutated TP53 is associated with poorer prognosis 
[15]. Myxoid liposarcoma occurs preferentially in deep soft tissue of the 
extremities, especially within the musculature of the thigh. 
 
Myxoid liposarcoma has unique genetic features [16]. More than 95% of the 
cases carry the FUS-DDIT3 fusion oncogene, and in the remaining cases a 
variant is present carrying the EWS-DDIT3 fusion oncogene, that is all of the 
FET family (Fig. 3). Further discussions are in section 1.6.  
1.3.4 Pleomorphic liposarcoma (PLS) 
Pleomorphic liposarcoma is an aggressive, high-grade tumor that constitutes 
about 10% of all liposarcoma types [12]. The morphology is of pleomorphic 
lipoblasts, often with hyper-chromatic, enlarged, and sometimes bizarre 
nuclei. It may mimic other tumors like pleomorphic undifferentiated sarcoma, 
and even carcinoma or melanoma, so the finding of lipogenic differentiation 
with lipoblasts is diagnostic. This subtype has a high risk of local recurrence 
and metastasis. 
Cytogenetically, pleomorphic liposarcoma more closely resembles those of 
other pleomorphic sarcomas. There are often numerous chromosomal 
imbalances, and no consistent translocation or ring chromosome has been 
identified [17] [18]. 
 
 1.3.5 Lipoma 
Lipoma is a benign fatty tumor usually growing subcutaneously on the arm, 
leg, or back, but it can be seen wherever there is fat. The morphology of 
lipoma is characterized by mature fat cells growing in lobes separated by thin 
collagen fibers, by scattered vessels and by a thin collagen capsule that often 
surrounds it. There is no cellular atypia and no mitosis. Lipomas rarely recur, 
except for intramuscular lipoma, which has a higher grade of local recurrence 
[19]. There are other subgroups of lipomas, for instance, angiolipoma, 
consisting of more vessels; fibrolipoma, consisting of more connective tissue; 
and chondrolipoma, consisting of cartilage.  
 
At chromosomal level, lipoma often shows translocations of the HMGA2 
gene, localized to 12q14.3, which plays an important role in a subset of 
lipomas [12]. This gene is located in the same chromosome segment as 
DDIT3 at chromosome 12. Further discussions are in section 1.5 and paper II. 
1.4 Stem cells 
Stem cells are non-specialized cells that exist in all multicellular organisms. 
They have two properties that distinguish them from other cell types. They 
can undergo a limitless number of cell divisions with self-renewal and they 
have the ability to mature to several different kinds of cell types [20]. Stem 
cells of mammalians are divided into three groups: embryonic stem cells, 
stem cells from the umbilicus and adult stem cells. Adult stem cells in the 
grown individual have the ability to repair wounded cells and tissues, for 
instance, satellite cells in muscle tissue.  
Since stem cells have the potential to mature to specialized cell types, they 
are in focus for intensive research and medical treatment using stem cells is 
now a reality [21-24]. 
1.4.1 Embryonic stem cells   
These are the first cells created in the very early embryonic life of all 
multicellular organisms. At day four of the embryo there are, in its inner 
sheet, totipotent stem cells with the ability to differentiate into any cell type 
in the body. These cells are thus not specialized and therefore very attractive 
to researchers. In humans, three germ cell layers (ectoderm, endoderm, and 
mesoderm) have evolved in a process called gastrulation, taking place in the 
third week of gestation. These three layers are now programmed to give rise 
to different kinds of tissue [1, 25-27].  
1.4.2  Mesenchymal progenitor/precursor cells  
At the end of the last century there was increased research on the 
mesenchymal cell system meaning bone marrow-derived stroma cells as well 
as mesenchymal stroma cells. The mesenchymal cell system was first 
described by Maureen Owen [28] and over the years a massive research 
effort concerning tissue reconstruction, cell transplantation, hematopoietic 
stem cell transplantation, and gene therapy has taken place. It has been shown 
that there are precursor cells/stem cells in adult tissue, and more simple stem 
cell systems that give rise to a few specialized cell types in skin and intestinal 
mucosa have been described [29]. 
The mesenchymal cell system has been shown to consist of bone marrow- 
derived mesenchymal stem cells that have the ability to stimulate 
regeneration, and some reports show that mesenchymal stem cells may 
migrate and give rise to a broader differentiation than previously believed. 
Among cultured mesenchymal precursor cells, bone-, cartilage-, fat-, and 
muscle differentiation has been reported [30-32].  
For the time being, it is unclear whether these multipotent abilities are a 
property of all neural or mesenchymal precursor cells, or if the studied 
populations are heterogeneous. The results suggest the occurrence of 
multipotent stem cells in normal tissue, and perhaps a common stem cell 
population that give rise to mesenchymal, neural, and hematopoietic 
differential pathways (Fig. 1).  
  
                     
Figure 1. Schematic picture of possible paths of differentiation from a totipotent stem 
cell to a more committed precursor cell. Red arrows show the possibility of 
redifferentiation to a more totipotent stem cell. 
 
 1.4.3 Satellite cells and other progenitor cells in 
muscle tissue 
In skeletal muscle, there is a distinct population of myogenic precursor cells 
called satellite cells. These cells lie on the surface of the muscle fiber beneath 
the basal lamina, but above the plasma membrane and are normally 
mitotically quiescent. They are small mononuclear cells, with virtually no 
cytoplasm, that have the potential to generate new muscle fibers, provide 
additional precursor nuclei to their parent muscle fiber, or return to a 
quiescent state [33, 34].   
Upon activation they proliferate and give rise to daughter myogenic precursor 
cells that form myotubes and, subsequently, new muscle fibers. In a cell 
culture fragmented muscle will transform into myoblasts before undergoing 
myogenic differentiation with fusion of multinuclear cells. The neural-cell 
adhesion molecule, NCAM (CD56, Leu-19), is a protein specifically 
expressed on the surface of human satellite cells as well as on regenerative 
skeletal muscle cells [35].  
Satellite cells have long been considered as committed, monopotent stem 
cells, but some reports claim that satellite cells may also be capable of 
differentiation into adipocytes and osteocytes in vitro,  indicating a pluri-
potent differentiation potential [33, 36-38]. 
Apart from satellite cells, skeletal muscle has also been reported to contain 
several other progenitor/stem cells such as multi-lineage stem cells including 
side population (SP)-cells), muscle-derived stem cells (MDSCs) and bone 
marrow-derived stem cells [36, 39-44]. SP-cells and MDSCs may have the 
potential to differentiate into several different cell types, including 
hematopoietic cells [45]. MDSCs have been shown to differentiate into a 
variety of lineages: skeletal muscle cells, glial cells, and endothelial cells. It 
has been suggested that the MDSC population are progenitors for satellite 
cells during development and regeneration [46]. 
A first step to separate satellite cells (muscle precursor cells) from other 
precursor cells may be to use the antibody CD56 (NCAM). 
1.5 Adipogenic differentiation 
1.5.1 Normal adipogenesis 
This is the process of cell differentiation by which precursor cells, 
preadipocytes, become adipocytes, and this process is essential for the 
molecular understanding of myxoid liposarcoma. 
Three classes of transcription factors have been identified that directly 
influence fat cell development. These include PPARγ, C/EBPs, and the basic 
helix–loop–helix family (ADD1/SREBP1c). The PPARγ protein forms a 
dimer with retinoid X receptor, and this complex regulates transcription of 
adipocytic genes [47]. 
There are several isoforms of the C/EBP family, and regulated expression is 
seen for several of them during adipogenesis. The different isoforms show 
stable homodimers and heterodimers. The C/EBPs belong to the basic-
leucine zipper class of transcription factors. C/EBPα expression rises after 
induction of PPARγ2, and these two transcription factors co-regulate. In 
cultured preadipocytic cell lines that have been induced to differentiate, 
C/EBPβ and δ mRNA and protein levels rise early and transiently [48, 49]. 
C/EBPα, on the other hand, is induced later in the differentiation process, 
slightly preceding the induction of most of the end-product genes of fat cells 
[47]. One of the anti-adipogenic transcription factors is DNA-damage-
inducible transcript 3, DDIT3, (Fig.2). 
 
 
 
Figure 2. Timing of CEBPB, CEBPA and DDIT3 expression in differentiation of 
mesenchymal stem cell to mature adipocyte. 
 
 
 1.5.2 The role of DDIT3 in adipogenesis 
The DDIT3 gene (also known as C/EBP-homologous protein (CHOP) or 
DNA-damage-inducible transcript 3, or “growth arrest” and DNA-damage- 
inducible protein (GADD153) encodes for a nuclear protein, which is a 
member of the C/EBP family. The DDIT3 protein forms stable heterodimers 
with the isoforms of C/EBPα and C/EBPβ [50]. Overexpression of DDIT3 
has been reported to block terminal adipocytic maturation and growth arrest 
[51-53]. We have shown that expression of DDIT3 in a low differentiated 
fibrosarcoma cell line results in morphological conversion towards a 
liposarcoma phenotype, paper I.  
The DDIT3 gene is also a key factor in cellular stress response and was 
identified by its transcriptional induction upon growth arrest and DNA 
damage [52, 54, 55]. 
  
1.6 Molecular biology of MLS 
1.6.1 Fusion genes 
A common activation mechanism for oncogenes in many types of sarcomas 
and lymphomas/leukemias, is the formation of fusion oncogenes. Around 700 
distinct fusion oncogenes are reported from human tumors [56]. A fusion 
gene is a hybrid gene formed from two previously separate genes where 
chromosome breaks coincident in time and space. It can occur as a result of: 
translocation, interstitial deletion, or chromosomal inversion. Often, fusion 
genes are oncogenes that cause cancer [57]. Chromosome translocations and 
gene rearrangements were first described in leukemia and lymphoma. The 
most famous is the Philadelphia chromosome translocation, t(9;22)(q34;q11), 
described by Nowell and Hungerford in 1960 [58], resulting in the formation 
of the BCR-ABL fusion gene [59, 60]. Several observations suggest that the 
formation of fusion oncogenes is more frequent than the tumors they are 
causing. Escape from stress responses leading to apoptosis or oncogene 
induced senescence, cell or tissue type dependence or interactions with other 
genetic variables are important for the final outcome of the formation of a 
new fusion oncogene [61-64]. 
1.6.2 The FET group of fusion oncogenes 
The sarcoma and leukemia causing the FET family of fusion oncogenes 
consists of the 5’ parts of one of three related genes FUS or EWSR1 or 
TAF15 juxtaposed with 3’ partners that encode various DNA binding 
transcription factors, see Fig. 3 [57, 61, 64, 65].  
One of the FET oncogenes, FUS-DDIT3, results from a t(12;16)-(q13;p11) 
chromosome translocation and has a causative role in initiation of 
MLS/RCLS [16, 65, 66]. 
 
 
 
Figure 3. The FET group of fusion oncogenes. The 5´parts of the FET family 
genes FUS, EWSR1 and TAF15 are fused to genes encoding various 
transcription factors (middle column). The respective fusion genes are found in 
the tumor types indicated in the right column. Observe the high degree of tumor 
type specificity for each FET fusion gene. 
 
1.6.3 The FUS- DDIT3 gene 
The fusion oncogene FUS-DDIT3 t(12;16)(q13;p11) is specific for myxoid 
liposarcoma. The DDIT3 gene on chromosome 12q13 fuses with the FUS 
gene on chromosome 16p11 or with EWS on 12q22 in MLS. FUS-DDIT3- 
and EWSR1-DDIT3- encoded proteins are believed to function as abnormal 
transcription factors interacting with differentiation and growth control of the 
tumor cells [12, 13, 67], (Fig.4). The protein is nuclear and considered to be 
an abnormal transcription factor where the N-terminal of FUS controls 
 
 DDIT3 with its strong transcriptional activation domain, fused to the 
dimerizing and DNA-binding elements of DDIT3 [62]. 
 
Figure 4.The t(12;16) translocation, which results from a fusion of chromosomes 12 
and 16, leads to the expression of a chimeric fusion protein having the N-terminal 
FUS domain fused to the entire DDIT3 protein. 
FUS-DDIT3 inhibits the development and the terminal adipocytic 
differentiation by blocking the C/EBPα activity [53]. This results in a cell 
population of partially committed pre-adipocytes that may progress to MLS.  
Experiments with transgenic mice have further demonstrated that FUS-
DDIT3 cause liposarcoma while normal DDIT3 or normal FUS did not result 
in liposarcoma. All these three transgenes showed normal white adipose 
tissue histology [68, 69]. A more recent study reported that FUS-DDIT3 
caused liposarcoma only in TP53 knockout mice [62]. 
1.7 Senescence 
Biologically senescence means the process of ageing. On cellular level, 
senescence occurs when normal cells cease to divide. In cell cultures, about 
50 cell divisions are possible, also known as replicative senescence-, the 
Hayflick phenomenon-, or the Hayflick limit [70, 71]. Telomere shortening is 
known to be an important mechanism in senescence [72-76]. There is a 
famous exception, the HeLa cells, which are the first human cells from a 
tumor and from which a permanent immortal cell line was created; these cells 
have the ability to propagate limitlessly in a cell culture [77]. HeLa cells and 
most tumor cells show an upregulated telomerase activity, thus providing 
capacity for unlimited proliferation [76, 78-80]. Most MLS/RCLS cases 
show an elevated telomerase expression caused by promotor mutations [81]. 
Cells can also be induced to senescence by stress caused by, for instance, 
certain toxins, irradiation, or the activation of certain oncogenes [82-84]. 
Senescence is thought to be an irreversible change, since chromatin is tightly 
packed by increased heterochromatin formation. Nuclear heterochromatin 
foci can be visualized by the presence of HP1γ. The pocket proteins RB1and 
RBL2 (P105 and P130, respectively) are important control hubs for cell 
cycle-proliferation driving transcription factors. RB1 is expressed in cycling 
cells, whereas RBL2 is expressed in resting and senescent cells [85-88]. 
 
Senescent cells has been shown to develop a senescence-associated secretory 
phenotype (SASP) and is characterized by the secretion of a wide range of 
growth factors, cytokines, extracellular matrix proteins and degradative 
enzymes, most of which can alter the local tissue microenvironment [89-92]. 
Of particular interest SASP is characterized by high level secretion of the 
cytokines, IL-6 and IL-8, which are key mediators of inflammation. The 
cytokines IL6 and IL8 are involved in induction and maintenance of 
senescence in human tissues [84] and these cytokines are also reported as 
autocrine growth or angiogenesis factors in several tumor types [89-92].  
Our group has previously showed that FUS-DDIT3, through interaction with 
NFKB and C/EBPβ directly induce expression of IL6 and IL8 by binding to 
the IL6 and IL8 promoters [93, 94].   
To understand the mechanisms that regulate IL-6 and IL-8 in association with 
senescence is important for understanding biological processes like tumor 
suppression and the development of cancer. 
1.7.1 Cell cycle, G1/S transition, in normal cells  
The cell cycle of normal cells is a series of events that takes place in a cell, 
leading to its division and duplication. The cell cycle consists of mitoses and 
interphase, divided into G1, S, and G2, during which the cell grows, 
duplicates its DNA and prepares for division. Cells that do not proliferate exit 
G1 phase and enter a quiescent stage, G0, until different growth factor signals 
promote the cell to re-enter the cell cycle, [6, 95, 96](Fig.5).  
1.7.2 Cell- cycle arrest 
This is a regulatory process that stops progression through the cell cycle 
during one of the normal phases. After mitosis, the cells enter G1 again, or go 
into G0, where they rest. At each of these phases, a checkpoint temporarily 
stops the cell cycle to allow the cell to decide if it should continue. The CDK 
inhibitors are important for this process. Some cells are programmed to 
duplicate infrequently, while damaged cells may need time for repair or 
destruction. On stimulation they re-enter the cell cycle. Radiation therapy 
 
 induces DNA damage and cells respond by activation of TP53 which induces 
arrest in G1, S, and G2 phases of the cell cycle, and in DNA repair [6].  
Cell-cycle arrest may be reversible or result in senescence. In fact, avoidance 
of arrest is a common adjustment in cancer. An even more common change is 
the activation of growth-promoting pathways such as MAPK and mTOR, 
which are involved in the senescent phenotype. Activation of MAPK and 
mTOR makes cancer cells pro-senescent [97, 98].  
 
Figure 5. A complex system of cell-cycle checkpoints and regulatory protein.s Cyclins, 
together with enzymes, called cyclin-dependent kinases (CDKs), controls the progression 
through the different phases of the cell cycle. The regulatory proteins are cyclin D, cyclin 
E, cyclin A, and cyclin B and are required as subunits for the catalytic activity of CDKs. 
CDK inhibitors are shown in red boxes. 
 
1.7.3 The role of TP53 
TP53The protein TP53, also known as p53, is essential in all multicellular 
organisms, where it senses various cell stress signals and functions as a tumor 
suppressor, preventing cancer. Because of its role in maintaining genetic 
stability by preventing genome mutation, TP53 is also called “the guardian of 
the genome”. The name relates to its molecular mass: it is in the 53 
kilodalton fraction of cell proteins [99]. Normally, the TP53 protein is 
continuously produced and degraded in the cell but stress signals and DNA 
damage, may trigger the increase and modification of TP53 proteins. TP53 
has a major function in growth arrest, DNA repair, and apoptosis, to avoid 
proliferation of cells containing abnormal DNA [6, 100]. TP53 arrest growth 
by holding the cell cycle at the G2/S regulation point where DNA repair 
proteins will have time to fix the damage in the cell [100]. Activated p53 
binds DNA, leading to the expression of several genes including microRNA 
miR-34a and WAF1/CIP1. They affect the expression of hundreds of down-
stream proteins and among them p21 that binds to the G1-S/CDK (CDK2) 
and S/CDK complexes, see fig 5, inhibiting their activity. When p21 is in 
complex with CDK2, the cell is not able to continue to the next stage of cell 
division. If TP53 is mutated, it will no longer bind DNA effectively and the 
p21 protein will, as a consequence,  not be able to act as the "stop signal" for 
cell division [101-103]. The cellular concentration of TP53 must be tightly 
regulated. While it can suppress tumors, high levels of TP53 may accelerate 
the aging process by excessive apoptosis. TP53 is also involved in stress-
induced senescence [104-106].  
The gene MDM2 is the major regulator of TP53. MDM2 is a proto-oncogene 
that promotes the cell cycle and encodes the nuclear phosphoprotein MDM2. 
In a negative feedback loop this protein is activated by TP53, and the 
encoded MDM2 binds to and inhibits the TP53 protein transactivation 
domain [107-109]. MDM2 also promotes degradation of TP53 by the 
ubiquitin system. If the TP53 gene is mutated, tumor suppression is severely 
reduced. This may allow abnormal cells to proliferate and result in cancer 
[110, 111]. A large amount of all human tumors contain mutated TP53 [7, 
112-114]. The majority of MLS cases carry normal TP53 genes. Compared to 
genetically complex sarcomas, MLS/RCLS is highly sensitive to radiation 
and chemotherapy suggesting a functional TP53 system [115-117]. A recent 
report show, however, that an FUS-DDIT3 transgene failed to induce tumors 
in mice, if not introduced in a TP53-deficient background. These results 
suggest that an impaired TP53 function could be an important factor in MLS 
[62]. This report prompted the investigations presented in paper IV. 
 
 2 AIM 
The objectives of this thesis were to investigate the behavior of myxoid 
liposarcoma and the role of the DDIT3 part of the fusion oncogene 
FUS-DDIT3. 
 
The main aims of papers I to V were as follows: 
 
 Paper I: To examine the mechanisms behind the tumor-type 
specificity of MLS/RCLS. 
 Paper II: To analyze the morphology directing role of DDIT3-
expression in different lipomatous tumors. 
Paper III:  To study the expression of proteins associated with 
growth control and senescence in MLS. 
Paper IV: To investigate the TP53 protein expression and function 
in MLS tissues, -derived cell lines, and xenografts. 
Paper V: To identify and characterize different cell populations in 
muscle tissue and their roles in development of 
MLS/RCLS.  
3 MATERIALS AND METHODS 
Formalin-fixed paraffin-embedded tumor tissue from 37 cases diagnosed and 
revalued as variant of lipomatous tumors was used for immunohistochemical 
analysis and RNA and FISH confirming analysis. Fresh human myoblast cell 
lines were used for comparison with MLS/RCLS tumor tissue from SCID-
mice xenografts derived from fibrosarcoma cell line HT1080. 
Immunohistochemistry and immunofluorescence microscopy   
Series of 5-μm tissue sections were cut from each biopsy, deparaffinised, 
rehydrated, boiled in microwave oven for 10 minutes for epitope retrievment 
and stained with the antibodies. Bound antibodies were visualized using the 
LSAB second antibody streptavidin biotin peroxidase system (DAKO). 
Stained sections were examined on a light microscope. 
For immunofluorescence analysis, cell cultures were washed twice with PBS 
and fixed in 4% paraformaldehyde in PBS. After two more washes in PBS, 
the slides were mounted in an anti-fade mount containing the DNA binding 
dye DAPI (4,6-diamidino-2-phenylindole dihydrochloride) (Olink 
Bioscience) and examined on a fluorescence microscope. 
FISH analysis 
Interphase FISH analysis of formalin-fixed tumor tissue was performed on 1-
4 µm paraffin sections. Three break-apart probes, DDIT3, FUS and EWSR1 
(Vysis Inc.), were used according to protocols supplied by the manufacturer. 
Nuclei were counterstained with 10 µl 4´,6´,-diamidino-2´-phenylindole 
dihydrochloride (DAPI). The sections were analyzed and re-analyzed by two 
independent reviewers. At least 100 nuclei per section were scored. The 
interpretation of intact, fusion and split signals was based on guidelines 
recommended by the manufacturer and from other clinical laboratories using 
this method. 
 
Genome-wide gene expression analysis 
Total RNA was extracted from cultured cells using the Trizol method 
(Invitrogen). The RNA was further purified using a Qiagen RNAeasy kit and 
stored at -140oC. Five µg of RNA was used for cDNA synthesis with Cy3 
and Cy5-labeled nucleotides. cDNA labeling and hybridization to microarray 
glasses was performed according to the Pronto! Plus Direct Labeling v1.2 
labeling and hybridization kit (InVitro, Sweden). 
Microarrays comprising approximately 27,000 unique probes representing 
23,707 genes were produced at the Swegene DNA Microarray Resource 
 
 Center, Department of Oncology, Lund University, Sweden 
(http://swegene.onk.lu.se).  
Image and data analysis 
Hybridized microarrays were scanned using an Agilent G2565AA microarray 
scanner (Agilent Technologies, Palo Alto, CA). Fluorescence intensities were 
extracted  using Gene Pix Pro 4.0 software (Axon Instruments Inc., Foster 
City, CA), and uploaded into Bio Array Software Environment (BASE) (Saal 
et al. 2002, http://base.thep.lu.se) for further analysis. The LOWESS 
algorithm 14 was used for normalization [118, 119]. 
Minimum median intensity was set to 1 to avoid data loss when the ratio 
between the samples and the reference cell line (wild-type HT1080) was 
being calculated. Genes with differences of at least threefold in signal 
intensity between the HT1080 reference cell line and the transfected HT1080 
variants were scored as upregulated or downregulated. Genes with a 
normalized intensity below 25 in the transfected cell lines were rejected from 
the lists of upregulated genes. Similarly, genes with a normalized intensity 
lower than 25 in the HT1080 reference were rejected from the lists of 
downregulated genes. RNA from the MLS cell line 402-91 was also tested, 
with the HT1080 cell line as a reference. 
Statistical analysis 
Statistical tests included mean value and standard deviation. To estimate the 
statistical significance of the overlap between differentially expressed genes 
in 402-91 cells and differentially expressed genes in the pFUS-DDIT3EGFP 
and pDDIT3EGFP transfected lines, two sets of genes corresponding to the 
up- and downregulated genes in 402-91 cells were selected at random from 
the total of 23,707 genes. Similarly, two sets of genes corresponding to up- 
and downregulated genes in one of the transfected lines were randomly 
selected. The number of genes that were identical in the randomly selected 
groups was then observed. This experiment was repeated 107 times for each 
pair of upregulated or downregulated gene sets. 
 
Muscle specimen 
Human skeletal muscle tissue samples were obtained from surgical excision 
at time of corrective surgery in conformity with Swedish legislation (S 441-
03). The muscle tissues were from different muscle compartments; m vastus 
lateralis, m trapezius, and m Sartorius. 
Each biopsy sample was collected in a sterile container containing transport 
medium (see below) and stored at 4˚C for up to 24 hours before processing. 
Ham’s F12 medium was used as transport medium. Phosphate-buffered 
saline (PBS) (pH 7, 2) was used for washings. Dissociation medium 
consisted of x% collagenase in Ham’s F12. The culture medium (CM) was 
composed of HAM’s F12 containing natrium bicarbonate (2,2g/L) and 
supplemented with 20% of fetal calf serum (Life technologies), penicillin and 
streptomycin. 
 
Cell culture 
The muscle tissue biopsy was dissociated according to a procedure earlier 
described [120, 121]. After being cleaned of tendons and fat, the biopsy was 
cut in fragments, rinsed in PBS, incubated in 10mL of dissociation medium 
and incubated at 37˚C in an incubator for 1 h with gentle shaking every 10 
minutes. The supernatant containing the released cells was decanted and 
filtered through a 100-μm nylon mesh into a tube containing 10 ml of CM.   
The remaining muscle tissue was further dissociated in fresh dissociation 
medium (10mL for 30 minutes) before being filtered in a tube to isolate 
additional free cells. Free cells were collected by centrifugation at 300 g for 
10 minutes and the pellet was resuspended in 5 mL of culture medium. The 
cells were seeded out in a 25 cm² flask in a total volume of 4 mL culture 
medium. The cultures were incubated at 37˚ in a humified atmosphere 
containing 5% CO2. Medium was changed 24 h after primary seeding and 
then every 4 days. Primary cultures were trypsinized and replated after 6-8 
days of incubation. 
 
Immuno magnetic cell fractionation. 
At first a fraction of the cultures (p2 and p3) was separated and incubated 
with NCAM in suspension and about 10-30 % of the cells were NCAM-
positive indicating the existence of myoblasts in the culture. 
The cells were separated by a magnetic cell sorting procedure according to 
Miltenvi Biotech’s MACS system using Goat Anti-Mouse IgG Micro Beads. 
A small fraction from each separated NCAM-positive and negative pool was 
incubated and stained with immunofluorescens in order to evaluate the 
separation. The NCAM-positive fraction was seeded at a density of 0, 8 x 
106 cells per 25 cm2  flask and the NCAM-negative fraction was seeded at a 
density of 3 x 106 cells. At second and seventh passage immunofluroscence 
tests on NCAM positivity was made. 
In vitro adipogenic assay 
Second to fourth or first frozen passages were used. The NCAM-negative and 
NCAM-positive populations were seeded in flaskettes and cultured in CM 
until they reached 70-100% confluence, after which the medium was changed 
to adipogenic-induction medium (Cambrex product PT3004 containing 
human recombinant insulin, dexamethasone, Indomethascin and IBMX) or  
to maintenance medium (MM; Cambrex product PT300X). The cells were 
treated with adipogenic induction medium for 3 days, followed by 1-3 days 
in MM. This was repeated three times. Control cultures were fed with MM 
 
 only following the same schedule. After completed cycles, the cells were 
cultured for 7 more days in MM with replacement of the medium every 2-3 
days. The cells were inspected using a microscope and accumulation of fat 
was assessed by staining the cells with Oil Red O after fixation with 4% 
buffered formalin. 
 
See the individual papers, I-V, for more detailed descriptions of the materials 
and other methods used. Experimental cell assays, vectors, transfections, 
western blot analysis, liquid chromatography-mass spectrometry, flow- 
cytometry and qPCR. 
4 RESULTS AND DISCUSSION 
4.1 Paper I 
Fusion oncogene FUS/DDIT3 and normal DDIT3 promotes liposarcoma 
like phenotype 
MLS tumor cells are characterized by the chromosomal aberration 
t(12;16)(q13;p11), which in most cases is the only cytogenetic abnormality. 
This translocation results in an FUS-DDIT3 fusion occurring in more than 
90% of cases [12]. The fusion gene FUS-DDIT3 encodes a protein consisting 
of the N-terminal half of the FUS protein juxtaposed to the DNA-binding 
basic leucine zipper transcription factor DDIT3 (also known as CHOP or 
GADD153) [16, 66]. The FUSDDIT3 protein can be found in the nuclei of 
MLS/RCLS cells and maintains the capacity of DDIT3 to form dimers 
with other leucine zipper-possessing proteins. These and other observations 
suggest that FUS-DDIT3 may act as an abnormal transcription factor.  
 
To understand the role of the FUS-DDIT3 fusion we designated vectors, 
pFUS-DDIT3EGFP, pDDIT3-EGFP, and pFUSaEGFP. Inoculation of 
transfected fibrosarcoma cell line HT1080 and MLS cell lines 402-912 and 
MLS 2645-94 in female FOX CHASE SCID mice was made, and the 
development of tumors was studied. 
 
Microscopic examination of sections from the tumors revealed that original 
HT1080 cells and pFUSaEGFP transfected cells grew as low-differentiated 
sarcomas, mainly with poorly defined or sinusoid blood vessels and necrotic 
areas. In contrast, the mice inoculated with the pFUS-DDIT3EGFP- or 
pDDIT3EGFP-expressing cells developed liposarcomas containing atypical 
lipoblasts of different sizes. Increased proportions of extracellular matrix and 
small myxoid pools were observed in tumors from the two pFUS-
DDIT3EGFP-transfected cell lines, but large amounts of the myxoid 
substance, as seen in many naturally occurring MLS tumors, were not found.  
 
The tumors from FUS-DDIT3- and DDIT3-transfected cells exhibited a 
capillary network morphology that was similar to networks of MLS/RCLS. 
Microarray-based comparison of HT1080, the transfected cells, and 
MLS/RCLS-derived cell lines showed that the FUS-DDIT3- and DDIT3-
transfected variants shifted toward an MLS/RCLS-like expression pattern. 
DDIT3-transfected cells responded in vitro to adipogenic factors by 
accumulation of fat and transformation to a lipoblast-like morphology.  
 
 In conclusion, the fusion oncogene FUS-DDIT3 and the normal DDIT3 
induce a liposarcoma phenotype when expressed in a primitive sarcoma cell 
line. MLS/RCLS may thus, develop from cell types other than preadipocytes. 
 
This may explain the preferential occurrence of MLS/RCLS in nonadipose 
tissues. In addition, development of lipoblasts and the typical MLS/RCLS 
capillary network could be an effect of the DDIT3 transcription factor partner 
of the fusion oncogene. 
 
4.2 Paper II 
DDIT3 protein expression in lipomatous tumors 
Adipocytic tumors are the most frequent types of soft tissue tumors, and they 
are characterized by the more or less prominent presence of lipoblasts or 
adipocytes [12]. Some of the adipocytic neoplasms are characterized by 
recurrent tumor type-specific genetic rearrangements. Most WDLS/DDLS 
cases contain amplified segments of chromosome 12q13-15 carried as ring 
chromosomes or large marker chromosomes [122-124]. The amplified 
regions contain many tumor-associated genes, and among these, DDIT3. 
MLS/RCLS carries rearranged DDIT3 fused to FUS or EWSR1 [66, 125]. 
DDIT3 is normally expressed in adipocyte differentiation together with the 
related transcription factors CEBPB and CEBPA [47]. The timing of 
expression of these factors is important for normal differentiation. In the 
context of liposarcoma development, aberrant DDIT3 expression may open 
an adipocytic differentiation pathway and promotes lipoblast development in 
small subpopulations of the tumor cells, as seen in WDLS/DDLS and 
MLS/RCLS. Overexpression of DDIT3 has, however, also been reported to 
block terminal adipocytic maturation and growth arrest [51-53]. These 
seemingly conflicting reports may be explained by a crucial timing of DDIT3 
expression in normal adipogenesis. DDIT3 could promote an adipocytic 
differentiation path in primitive mesenchymal cells but block later stages of 
development.  
  
In the previous study we showed that expression of DDIT3 in a low- 
differentiated fibrosarcoma cell line results in morphological conversion 
towards a liposarcoma phenotype [126]. These observations suggest that 
expression of DDIT3 protein could be a common phenotype-determining 
factor for several types of lipomatous tumors. 
In this study we tested this hypothesis by investigating the expression of the 
DDIT3 protein in three different subtypes of liposarcoma and in common 
lipoma. We further evaluated the role of DDIT3 expression by studying 
lipoblast formation in cultured liposarcoma cells treated with adipogenic 
factors.  
Paraffin embedded sections were obtained from our pathology department in 
conformity with Swedish legislation. The material consisted of 11 lipomas, 
11 PLS, 10 WDLS and 16 MLS/RCLS. The GOT3 cell line, established from 
a WDLS tumor was used to study adipogenic differentiation. 
 
Our results show that DDIT3 is expressed in subpopulations of tumor cells in 
all 4 investigated lipomatous tumor types. There were no obvious differences 
between the number of DDIT3-expressing cells and the more aggressive 
DDLS and RCLS compared to WDLS and MLS.  
Furthermore, DDIT3 was expressed at comparable levels in benign lipomas. 
Only a minority of DDIT3 expressing sarcoma cells responded to adipogenic 
conditions in vitro, indicating a complex role for DDIT3 as a phenotype-
directing factor in lipomatous tumors. 
 
We speculate that only a small minority of the cells would make it through 
the block and differentiate to lipoblasts. This would also explain the lack of 
correlation between numbers of DDIT3-expressing cells and numbers of 
lipoblasts in the investigated tumors. To test this hypothesis, the 
WDLS/DDLS-derived cell line GOT3 was analyzed after adipogenic 
treatment. This cell line carries a large chromosome 12-derived amplicon 
including the DDIT3 gene and was found to express DDIT3 constitutively in 
almost all cells [124]. A limited accumulation of lipids in sporadic cells was 
seen under standard culture. Transfer to adipogenic culture conditions 
resulted in lipid accumulation and adipoblast development, but only in a 
minority of the cells.  
These and our previous results show that expression of DDIT3 or FUS-
DDIT3 can promote a liposarcoma phenotype in human fibrosarcoma cells 
[126]. FUS-DDIT3 transfected mesenchymal stem cells cause MLS/RCLS-
like tumors when injected in mice, and FUS-DDIT3 transfection transforms 
3T3 mouse fibroblasts. This shows that FUS-DDIT3 is a powerful oncogene.  
 
In contrast, forced expression of DDIT3 protein in mesenchymal cells or in 
transgenic mice gave no evidence of transformation or tumorigenic activity. 
The normal DDIT3 protein can thus not be considered a driving oncoprotein. 
Aberrantly expressed, it may, however, act as a promoting factor or/and 
tumor-type directing factor by interfering with the adipocyte differentiation 
program.  
 
 4.3 Paper III 
MLS contains a major population of senescent cells 
MLS is a slow-growing tumor but, 10%-15% of the cases show hyper 
cellular round cell morphology (RCLS) with less myxoid component that is 
associated with an unfavorable prognosis[12]. 
In the present study, we have employed immunohistochemistry (IHC) and 
flow cytometry, and analyzed a cohort of 17 MLS/RCLS tumors that were 
not previously treated with radiation or drugs, for expression of proteins 
associated with growth control and senescence. 
Flow cytometry of two human MLS/RCLS tissues showed 94% and 96% of 
the cells in G1. These results are in agreement with our previous findings that 
that only a small percentage express cyclin A and have entered the S-phase 
[127]. The majority of the tumor cells are thus arrested in G1, although they 
express high levels of G1 cyclins, CDK4/6 and CDK2. 
   
The pocket protein RB1 is expressed in cycling cells, whereas RBL2 is 
expressed in resting and senescent cells [85, 86, 88, 106]. Our IHC analysis 
of RB1 and RBL2 expression showed that large subpopulations of the 
MLS/RCLS tumor cells expressed the G0/senescence associated RBL2.  
 
We previously showed that FUS-DDIT, through interaction with NFKB and 
C/EBP directly induced expression of IL6 and IL8 by binding to the IL6 and 
IL8 promoters [127]. These cytokines have also been implicated as autocrine 
growth or angiogenesis factors in various tumor types [128-131]. More 
recently IL6, and IL8 have been implicated in induction and maintenance of 
senescence in human tissues[132]. 
 
We tested MLS/RCLS tumor cell lines for growth and survival dependence 
of IL6 in vitro but detected no effects of treatment with IL6 receptor blocking 
antibodies. Instead, IL6 may, together with IL8, be a part of a senescence 
mechanism in MLS/RCLS. The fusion oncoprotein thus promotes a cytokine 
expression profile that is typical for senescent cells. The senescence-
associated IL8 receptor beta (CXCR2) was also expressed on a large 
proportion of the tumor cells. 
 
All together these results tell us that MLS contains a major population of 
senescent cells. This is also consistent with clinical behavior of this type of 
slowly growing tumor.  
4.4 Paper IV 
The MLS cells express functional TP53 protein 
The vast majority of the MLS/RCLS tumors carry normal TP53 genes, 
and secondary changes are few and rare, even when relapses occur after 
many years [116]. Compared to genetically complex sarcomas, 
MLS/RCLS is highly sensitive to radiation and chemotherapy, supporting 
the view that the tumor cells maintain a functional TP53 system [133]. A 
recent study shows however, that a FUS-DDIT3 transgene fail to induce 
tumors in mice if not introduced into a TP53-deficient genetic background 
[62]. This indicates that impaired TP53 function could be an important factor 
in MLS development. These partially conflicting observations prompted us to 
investigate the status of the TP53 protein and function in MLS tissues, 
derived cell lines, and xenografts.  
 
In the present investigation we examined the expression and function of the 
TP53 gene in four MLS-derived cell lines, three with normal and one with a 
mutated TP53 gene. Their genomes were searched for mutations and TP53 
transcripts analyzed for splicing variants.  
These results show that, except for the TP53-mutated DL221, the cell lines 
contained normal TP53 genes. TP53 protein from one MLS-derived cell line 
was immune precipitated and analyzed by mass spectroscopic analysis. TP53 
expression was analyzed by immunohistochemistry, and our analysis of 
seven MLS/RCLS tumor tissue cases showed very few expressing cells 
suggesting normal TP53 genes[134].  
 
In contrast to tumor tissues, the MLS-derived in vitro cultured cell lines 
MLS402-91, 1765-91, 2645-94, and DL221 all expressed TP53 protein, as 
shown by our western blot and immune-fluorescence analysis. The reason for 
the strong TP53 expression in cultured MLS cells is not understood. Cell 
stress caused by the in vitro culture conditions is a plausible explanation and 
supported by the fact that freshly explanted cells from MLS tissues rapidly 
start to express the TP53 protein and enter a senescent stage within a few 
passages. 
Radiation-induced expression changes were followed by western blot and 
immunofluorescence analysis. Expression of P21 (also known as CDKN1A, 
WAF1 or CIP1) is reportedly induced by activated functional TP53 after 
radiation damage [135, 136]. Expression of P21 was elevated in all radiation-
treated MLS derived cells, although the induction was much weaker in DL-
221 and MLS2645-94.  
 
 
 We conclude that a normal TP53 was produced in three of four investigated 
MLS cell lines. Our IHC data together with investigations from other groups 
suggest that TP53 mutations are uncommon in MLS/RCLS. Normal 
radiation-induced TP53 function was observed in two of three lines with 
normal TP53 genes. The FUS-DDIT3 fusion protein had no effect on 
radiation-induced modifications of TP53 or TP53-induced P21 expression. 
Our results suggest that most cases of MLS/RCLS contain functional 
TP53. 
4.5 Paper V 
MLS-derived cells express genes that are typical both for myotube 
committed satellite cells and for SP cells 
Myxoid/round cell liposarcoma (MLS/RCLS) develops within large muscles, 
most often in the thigh, suggesting that the tumors develop from unidentified 
cell types of this tissue [12].  
 
The present study is a first attempt to identify possible cells of origin for 
MLS/RCLS among human muscle-derived cell populations.  With this aim, 
we isolated cells from normal human muscle tissues [121, 137], and used 
immunomagnetic methods to isolate satellite cells and SP cells with the 
antibody NCAM (CD56) [35]. The subpopulations were functionally tested 
by in vitro differentiation assays, and micro-array methods were employed to 
define myoblast- and SP-cell-specific expression patterns and compare them 
with those of MLS-derived cell lines.  
 
Our results show a gene expression pattern of the MLS/RCLS cell lines that 
share features both with myoblasts and SP cells from this tissue 
compartment. Possible target cells could be, as yet uncharacterized, myoblast 
precursors, which remain NCAM negative. This would also be compatible 
with the capacity of the MLS/RCLS-specific fusion gene FUS-DDIT3 to 
induce a liposarcoma phenotype when expressed in low-differentiated 
sarcoma cells.   
 
5 CONCLUSIONS 
In this thesis we have addressed the question of the tumor-type specificity of 
the fusion oncogene FUS-DDIT3 and normal DDIT3 in the context of 
liposarcoma. 
Our results show that the genes FUS-DDIT3 and DDIT3 have instructive 
roles in the morphology of liposarcoma. They also explain why liposarcoma 
may arise in other compartments than adipose tissue. 
 
Previous studies have shown peculiar pattern of growth controlling genes in 
MLS/RCLS. We have studied the expression of growth- and cell senescence 
associated proteins and concludes that MLS/RCLS tumors contain large 
subpopulations of senescent cells. We also show that expression of FUS-
DDIT3 causes a slower growth in vitro and in vivo. 
 
Human sarcomas can be divided into two main categories based on TP53 
function leading to genetic complexity or stability. Here we conclude that 
most MLS/RCLS tumors have functional TP53 genes, which also explain 
their genetic stability and radiation sensitivity. 
 
The majority of MLS/RCLS arise inside skeletal muscles and not in adipose 
tissue. This paradox is partially explained by the instructive role of the fusion 
oncogene. Recent studies suggest that mesenchymal stem cell may be the cell 
of origin for MLS/RCLS. 
By comparative gene-expression analysis of muscle-derived normal cells 
with MLS tumor cells we conclude that MLS tumors may derive from an 
immature muscle precursor cell. 
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